drugset / Trial / NCT01549301

Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.

NCT01549301

Phase 1 Completed 128 enrolled Azidus Brasil
RandomizedCrossoverOpen-labelTreatment

Summary

The primary aim of this study is to compare the pharmacokinetic and pharmacodynamic effects of two commercial preparations of filgrastim (T and C), after single dose via subcutaneous or intravenous administration at a concentration of 5 mcg/kg or 10 mcg/kg in healthy subjects through the alteration in the pharmacokinetic and pharmacodynamic parameters (measurement of serum levels of G-CSF and absolute neutrophil count - ANC).

Timeline

Start
2012-08
Primary completion
2013-08
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic 5 ug/kg Subcutaneous
Subject filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

No indication recorded.